|
Name |
Sphaeropsidin A
|
Molecular Formula | C20H26O5 | |
IUPAC Name* |
(1R,2R,5R,9S,10S)-5-ethenyl-2,9-dihydroxy-5,11,11-trimethyl-16-oxatetracyclo[7.5.2.01,10.02,7]hexadec-6-ene-8,15-dione
|
|
SMILES |
C[C@@]1(CC[C@]2(C(=C1)C(=O)[C@@]3([C@@H]4[C@@]2(CCCC4(C)C)C(=O)O3)O)O)C=C
|
|
InChI |
InChI=1S/C20H26O5/c1-5-17(4)9-10-19(23)12(11-17)13(21)20(24)14-16(2,3)7-6-8-18(14,19)15(22)25-20/h5,11,14,23-24H,1,6-10H2,2-4H3/t14-,17-,18-,19+,20+/m0/s1
|
|
InChIKey |
FEKFUWWVNCCROX-SQWSIXGCSA-N
|
|
Synonyms |
SPHAEROPSIDIN A; LL-S491beta; Sphaeropsidin A, (+)-; 9F59Q9OS1I; CHEBI:69494; (4aR,4bR,7R,10S,10aS)-7-Ethenyl-1,2,3,4,4b,5,6,7,10,10a-decahydro-4b,10-dihydroxy-1,1,7-trimethyl-9H-10,4a-(epoxymethano)phenanthrene-9,12-dione; 38991-80-9; 9H-10,4a-(Epoxymethano)phenanthrene-9,12-dione, 7-ethenyl-1,2,3,4,4b,5,6,7,10,10a-decahydro-4b,10-dihydroxy-1,1,7-trimethyl-, (4aR,4bR,7R,10S,10aS)-; Antibiotic LL-S491beta; UNII-9F59Q9OS1I; MLS003373242; CHEMBL1834675; ANTIBIOTIC LL-S491.BETA.; NSC765878; NSC-765878; SMR002047999; Q27137833; (2R,4aR,4bR,8aS,9S)-4a,9-dihydroxy-2,8,8-trimethyl-2-vinyl-4,4a,5,6,7,8,8a,9-octahydro-2H-9,4b-(epoxymethano)phenanthrene-10,12(3H)-dione
|
|
CAS | 38991-80-9 | |
PubChem CID | 51361447 | |
ChEMBL ID | CHEMBL1834675 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 346.4 | ALogp: | 2.6 |
HBD: | 2 | HBA: | 5 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 83.8 | Aromatic Rings: | 4 |
Heavy Atoms: | 25 | QED Weighted: | 0.563 |
Caco-2 Permeability: | -4.919 | MDCK Permeability: | 0.00002150 |
Pgp-inhibitor: | 0.994 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.034 | 20% Bioavailability (F20%): | 0.064 |
30% Bioavailability (F30%): | 0.007 |
Blood-Brain-Barrier Penetration (BBB): | 0.954 | Plasma Protein Binding (PPB): | 83.78% |
Volume Distribution (VD): | 1.605 | Fu: | 14.94% |
CYP1A2-inhibitor: | 0.013 | CYP1A2-substrate: | 0.954 |
CYP2C19-inhibitor: | 0.22 | CYP2C19-substrate: | 0.732 |
CYP2C9-inhibitor: | 0.191 | CYP2C9-substrate: | 0.059 |
CYP2D6-inhibitor: | 0.016 | CYP2D6-substrate: | 0.083 |
CYP3A4-inhibitor: | 0.823 | CYP3A4-substrate: | 0.841 |
Clearance (CL): | 2.882 | Half-life (T1/2): | 0.162 |
hERG Blockers: | 0.023 | Human Hepatotoxicity (H-HT): | 0.456 |
Drug-inuced Liver Injury (DILI): | 0.04 | AMES Toxicity: | 0.783 |
Rat Oral Acute Toxicity: | 0.254 | Maximum Recommended Daily Dose: | 0.666 |
Skin Sensitization: | 0.179 | Carcinogencity: | 0.631 |
Eye Corrosion: | 0.012 | Eye Irritation: | 0.217 |
Respiratory Toxicity: | 0.899 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001409 | 0.722 | D0G6AB | 0.252 | ||||
ENC002041 | 0.541 | D04GJN | 0.250 | ||||
ENC002830 | 0.456 | D0L2LS | 0.245 | ||||
ENC002906 | 0.419 | D0Z1XD | 0.243 | ||||
ENC002831 | 0.413 | D0EP0C | 0.233 | ||||
ENC002829 | 0.412 | D06AEO | 0.232 | ||||
ENC002832 | 0.411 | D0IX6I | 0.232 | ||||
ENC002833 | 0.376 | D0Q6NZ | 0.231 | ||||
ENC002083 | 0.368 | D0Q4SD | 0.228 | ||||
ENC001070 | 0.356 | D0I2SD | 0.227 |